This session brings together two leading cardiology experts to explore the critical challenge of hyperkalemia (HK) in heart failure management. The discussion will delve into the interplay between potassium levels, RAAS inhibitor therapy, and guideline-directed medical therapy (GDMT), highlighting how clinicians can balance treatment benefits with potassium management.

With a strong focus on real-world clinical decision-making, the session will cover practical strategies to identify and manage HK while supporting the continued use and optimization of life-saving heart failure therapies. It will also address common clinical challenges and considerations when HK becomes a potential barrier to achieving optimal GDMT.